Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-12-15Clinical Trial Update: Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis [Phase 1, Phase 2]
This document reports a completed Phase I/II clinical trial evaluating autologous bone marrow-derived mesenchymal stem cells for relapsing-r…
-
CLINICAL_TRIALS trial_result · 2016-11-22Clinical Trial Update: Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta. [Phase 1]
This is a completed Phase 1 safety study evaluating olesoxime in patients with Relapsing-Remitting Multiple Sclerosis who are treated with i…
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis [Phase 4]
Phase 4 biomarker study evaluating Fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis has been completed.
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: Fingolimod -Response According to Coping - Evaluation [Phase 4]
Phase 4 clinical trial evaluating Fingolimod response according to coping strategies in relapsing-remitting multiple sclerosis has completed…
-
CLINICAL_TRIALS trial_result · 2016-10-25Clinical Trial Update: Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis
A completed clinical trial evaluating switching relapsing-remitting multiple sclerosis patients from daily 20 mg glatiramer acetate injectio…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-09-14Clinical Trial Update: Dose-finding Study of MT-1303 [Phase 2]
A Phase 2 dose-finding study of MT-1303 for relapsing-remitting multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2016-09-14Clinical Trial Update: Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod
A completed clinical trial evaluated disease control when switching RRMS patients from natalizumab to fingolimod.
-
CLINICAL_TRIALS trial_result · 2016-09-12Clinical Trial Update: Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis [NA]
This document reports the completion of a clinical trial evaluating the effects of an electromechanical gait trainer in patients with Relaps…
-
CLINICAL_TRIALS trial_result · 2016-09-05Clinical Trial Update: Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS
A single-arm in vivo 7T MRS study evaluating whether Tecfidera (dimethyl fumarate) can restore glutathione synthesis in patients with relaps…
-
CLINICAL_TRIALS trial_result · 2016-08-30Clinical Trial Update: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis [Phase 2]
This clinical trial update reports safety and efficacy data from a Phase 2 extension study of daclizumab high yield process (DAC HYP) in par…
-
CLINICAL_TRIALS trial_result · 2016-08-16Clinical Trial Update: Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis [Phase 2]
This update notes the completion of a Phase 2 study evaluating whether the compound GSK239512 can promote remyelination in people with relap…
-
CLINICAL_TRIALS trial_result · 2016-08-01Clinical Trial Update: A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED) [Phase 2]
Phase 2 study evaluating MK0812 for disease activity in Relapsing-Remitting Multiple Sclerosis has been terminated.
-
CLINICAL_TRIALS research · 2016-07-28Clinical Trial Update: Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 2]
Phase 2 proof-of-concept trial investigating RHB-104 as add-on to interferon beta-1a in relapsing-remitting multiple sclerosis has completed…
-
CLINICAL_TRIALS withdrawal · 2016-07-20Clinical Trial Update: Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS [Phase 4]
A Phase 4 trial evaluating the mechanism of action of dimethyl fumarate in relapsing multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2016-07-12Clinical Trial Update: Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) [Phase 2]
A Phase 2 extension study in relapsing-remitting multiple sclerosis was terminated; results were posted on 2016-07-12.
-
CLINICAL_TRIALS trial_result · 2016-07-11Clinical Trial Update: Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis [Phase 3]
Phase 3 trial comparing daclizumab high-yield process (BIIB019) with interferon beta-1a in relapsing-remitting multiple sclerosis reports ef…
-
CLINICAL_TRIALS trial_result · 2016-07-11Clinical Trial Update: Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis [Phase 2]
Phase 2 safety and efficacy study of Daclizumab High Yield Process for relapsing-remitting multiple sclerosis completed. Results were posted…
-
CLINICAL_TRIALS trial_result · 2016-07-11Clinical Trial Update: Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment [Phase 2]
A Phase 2 trial evaluated adding VigantOL Oil (vitamin D3) versus placebo to Rebif in patients with relapsing-remitting multiple sclerosis; …
-
CLINICAL_TRIALS trial_result · 2016-06-23Clinical Trial Update: PK and PD Study of Natalizumab in Pediatric Subjects With RRMS [Phase 1]
A Phase 1 pharmacokinetic/pharmacodynamic study of natalizumab in pediatric relapsing-remitting multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2016-06-16Clinical Trial Update: A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 2]
Phase 2 trial evaluating the combination of Copaxone (glatiramer acetate) and estriol in relapsing-remitting multiple sclerosis; results wer…
-
CLINICAL_TRIALS trial_result · 2016-06-09Clinical Trial Update: Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA [Phase 4]
Phase 4 trial update describing strategies for managing infusion-associated reactions in relapsing-remitting multiple sclerosis patients tre…
-
CLINICAL_TRIALS trial_result · 2016-06-09Clinical Trial Update: Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis [Phase 4]
This Phase 4 trial update indicates that the study evaluating the long-term effect of fingolimod on circulating immunocompetent mononuclear …
-
CLINICAL_TRIALS trial_result · 2016-06-07Clinical Trial Update: A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 [Phase 4]
A 12-month, open-label, multicenter Phase 4 trial evaluating health outcomes of fingolimod (FTY720) in relapsing-remitting multiple sclerosi…
-
CLINICAL_TRIALS trial_result · 2016-06-07Clinical Trial Update: Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
This clinical trial update reports real-world outcomes for patients with relapsing-remitting multiple sclerosis who switch to Tecfidera afte…
-
CLINICAL_TRIALS trial_result · 2016-06-03Clinical Trial Update: Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis [Phase 1]
Phase 1 study evaluating immune and microRNA responses to recombinant interferon beta in healthy volunteers and relapsing-remitting multiple…